Category: Legislative

South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report.  It would be a significant blow to 340B providers who have counted

U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.

Manchin

West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

Manchin said of the BBA bill on Dec. 19, “I cannot vote to

The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.

Pharmaceutical Research and Manufacturers of America (PhRMA) called it a

The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.

The committee released the …

The Democratic-led U.S. House Oversight and Reform Committee is holding a hearing this Thursday to review the findings of its nearly three-year investigation into drug industry pricing and business practices.

The Dec. 9 hearing starts at 10:30 a.m. Eastern. It’s

Elise Stefanik, the third highest-ranking Republican in the U.S. House, is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Stefanik (R-N.Y.) announced her co-sponsorship of Reps. Doris

U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.

Senate President Pro Tempore Leahy, 81, announced on Nov. 15 that he

After five major court decisions on the 340B contract pharmacy standoff and no quick resolution in sight, expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in

Congressional debate over lowering drug prices has shifted to the U.S. Senate following House passage of the $1.75 trillion Build Back Better social spending bill on Friday.

Congress has been on break this week for the Thanksgiving holiday. It returns